Dynacure Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for DYN101 for Myotubular and Centronuclear Myopathies (CNM)
- Thursday, July 30, 2020, 7:04
- Finance
- Add a comment
STRASBOURG, France and PHILADELPHIA, July 30, 2020 /PRNewswire/ — Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted rare pediatric…
About the Author
adminasapcorp has written 41525 stories on this site.